NVN Liquidation (OTCPK:NOVN.Q) - Aandelenkoers, Nieuws & Analyse

NOVN.Q Overzicht aandelen

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Meer informatie

NOVN.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De omzet groeide het afgelopen jaar met 512.7%

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Negatief eigen vermogen

Heeft geen betekenisvolle marktkapitalisatie ( $28 )

De laatste financiële rapporten zijn ouder dan 6 maanden

NVN Liquidation, Inc. Concurrenten

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Baudax Bio

OTCPK:BXRX.Q

US$52.0

DMK Pharmaceuticals

OTCPK:DMKP.Q

US$10.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NVN Liquidation
Historische aandelenkoersen
Huidige aandelenkoers	US$0.000001
52 Week Hoogtepunt	US$1.38
52 Week Laag	US$0.000001
Bèta	1.65
11 maand verandering	-99.88%
3 maanden verandering	-99.00%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Rendement voor aandeelhouders

	NOVN.Q	US Pharmaceuticals	US Markt
7D	-99.9%	1.6%	2.2%
1Y	-100.0%	10.0%	31.7%

Rendement versus industrie: NOVN.Q presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 10 % opleverde.

Rendement versus markt: NOVN.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is NOVN.Q's price volatile compared to industry and market?
NOVN.Q volatility
NOVN.Q Average Weekly Movement	1,535.8%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van NOVN.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van NOVN.Q is het afgelopen jaar gedaald van 1617% naar 1536%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	90	Scott Plesha	www.novan.com

NVN Liquidation, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NVN Liquidation zich tot de beurswaarde?
NOVN.Q fundamentele statistieken
Marktkapitalisatie	US$28.00
Inkomsten(TTM)	-US$32.05m
Inkomsten(TTM)	US$24.92m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is NOVN.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NOVN.Q resultatenrekening (TTM)
Inkomsten	US$24.92m
Kosten van inkomsten	US$24.45m
Brutowinst	US$473.00k
Overige uitgaven	US$32.52m
Inkomsten	-US$32.05m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.14
Brutomarge	1.90%
Nettowinstmarge	-128.61%
Schuld/Eigen Vermogen Verhouding	-1,164.1%

Hoe presteerde NOVN.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

NOVN.Q Overzicht aandelen

Beloningen

Risicoanalyse

NVN Liquidation, Inc. Concurrenten

OTCPK:PLXP.Q

US$30.0

OTCPK:BXRX.Q

US$52.0

OTCPK:DMKP.Q

US$10.0

OTCPK:RVLP.Q

US$111.0

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

NVN Liquidation, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet